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Non-resolving Community Acquired Pneumonia (CAP) due to
Blastomyces dermatitidis (Pulmonary Blastomycosis): Case Report
and Review of Literature
*Johnson Britto1

Abstract
In this case report, we describe a case of progressive acute pulmonary blastomycosis in a healthy
adult living in Kentucky, initially presenting with flu like illness with a left sided consolidation, who
did not respond to antibiotic therapy. Patient’s clinical condition deteriorated with development
of necrotizing bronchopneumonia, mediastinal lymphadenopathy, tree-in-bud reticulonodularity
and pleural effusion. A diagnosis of progressive pulmonary blastomycosis was established by
radiological findings as well as transbronchial needle aspiration cytology and bronchoalveolar lavage
culture demonstrating Blastomyces dermatitidis. Patient showed significant clinical improvement
with resolution of pulmonary lesions on antifungal treatment. Since symptoms of blastomycosis are
often similar to the symptoms of flu or other lung infections, our case highlights the importance
of maintaining a high index of suspicion and appropriate microbiologic and histologic evaluation
especially in patients who live in or have traveled to areas endemic for blastomycosis and are not
responding to antibiotic therapy. Early diagnosis coupled with prompt initiation of antifungal treatment
may lead to favorable outcomes.
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Introduction
Blastomycosis is caused by the dimorphic fungus Blastomyces
dermatitidis. Blastomycosis is an endemic mycosis that occurs
in defined geographic areas and usually in regions that are warm
with soil rich in organic debris, such as decaying vegetation
and decomposed wood [1, 2]. In North America, blastomycosis
usually occurs in the southeastern and south-central states
that border the Mississippi and Ohio Rivers, the midwestern
states and Canadian provinces that border the Great Lakes
and Saint Lawrence Riverway [1-5]. Blastomycosis is a
systemic pyogranulomatous infection. The clinical spectrum of
blastomycosis is varied, including asymptomatic infection,
acute or chronic pneumonia, extrapulmonary and disseminated
disease. The lungs are the most common site of infection,
followed by the skin, bones, and genitourinary system. A subset
of individuals with acute pulmonary blastomycosis can progress
to fulminant multi-lobar pneumonia and acute respiratory
distress syndrome [10]. Diagnostic delays are not uncommon
and often result in increased morbidity and mortality. Here,
we describe a case of progressive pulmonary blastomycosis in a
young healthy adult.

Case Report
A 31 year-old African American female with no significant past
medical history presented to an outside hospital complaining
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of 1-week history of subjective fevers and chills, fatigue,
nonproductive cough, dyspnea and left sided pleuritic chest
pain.
Initial vital signs were temperature 100.5ºF, heart rate 95
beats per minute, respiratory rate 18 breaths per minute,
blood pressure 148/88 mm Hg, and oxygen saturation 99% on
room air. On physical exam, she had no respiratory distress,
no lymphadenopathy, examination of the respiratory system
revealed bilateral vesicular breath sounds and crackles at the
left lower lobe. Examination of the cardiovascular system,
abdomen, central nervous system, and skin were unremarkable.
Initial diagnostic laboratory work up showed leucocyte
count of 14,500 cells/mm3 (76% segmented neutrophils, 13%
lymphocytes and 11% monocytes), hemoglobin 12.9 g/dl,
hematocrit 38.9% and platelet count 316,000/mm3. Serum
electrolytes, renal function, and liver function tests were
normal. Rapid Influenza test was positive for Influenza A.
Urine streptococcal and legionella antigens were negative.
Chest X-ray (CXR) showed an ovoid superior segment left lower
lobe focus of consolidation (Figure 1).
A diagnosis of Influenza A and possible community acquired
bacterial pneumonia was made and patient was admitted to the
hospital. She was started on oral oseltamivir and intravenous
ceftriaxone and azithromycin.
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Due to a lack of clinical improvement after three days of
antimicrobial treatment, chest computed tomographic
(CT) scan was obtained that showed a dense consolidation
involving the majority of the left lower lobe, and a trace left
pleural effusion (Figure 2). Bronchoscopy was performed.
Bronchoscopy did not show any endobronchial lesions, Gram’s
stain of bronchoalveolar lavage (BAL) of left lower lobe showed
many white blood cells and rare Gram-positive bacilli, culture
grew 10,000-100,000 CFU/mL of normal respiratory flora,
KOH Prep was negative for fungal elements, acid-fast bacilli was
negative, as was legionella PCR. BAL sample was not sent for
cytological analysis. She was hospitalized for five days during
which there was no significant change in her clinical status and
she remained without clinical improvement or deterioration.
She completed a five day course of oral oseltamivir. Intravenous
antimicrobials were switched to oral levofloxacin to complete
a course of seven days and she was discharged home with
outpatient follow up.

Vital signs at the time of initial evaluation in our emergency
department were as follows: temperature 102.0ºF, heart rate
115 beats per minute, respiratory rate 20 per minute, blood
pressure 126/66 mm Hg, and oxygen saturation 95% on
room air. On physical exam, she had no respiratory distress,
no lymphadenopathy, examination of the respiratory system
revealed diminished breath sounds, whisper pectoriloquy,
egophony and crackles at the left lower lobe, examination of the
cardiovascular system, abdomen, central nervous system and
skin were unremarkable.
Pertinent initial diagnostic laboratory work up showed leucocyte
count of 33.3 x 103 cells/mm3 (83% segmented neutrophils,
12% lymphocytes and 4% monocytes). Hemoglobin 11.5 g/
dl, hematocrit 34% and platelet count 539,000/mm3. Serum
electrolytes revealed serum sodium 139 mmol/L, potassium of
3.1 mmol/L, renal function revealed blood urea nitrogen and
serum creatinine of 6.0 mg/dL and 0.46 mg/dL respectively,
liver function tests revealed alkaline phosphatase 255 U/L, AST
145 U/L, ALT 110 U/L, albumin 3.1 g/dL, and total bilirubin 1.0
mg/dL.
Chest X-ray (CXR) showed progression of the radiological
changes, in the intervening 10 days from the initial imaging, with
a new development of worsening left lower lobe consolidation
with cavitary changes consistent with necrotizing pneumonia
(Figure 3).

Figure 1. Initial Chest X-ray (CXR) showing ovoid superior segment left
lower lobe consolidation.

Chest computed tomography (CT) scan was obtained that
showed dense necrotizing bronchopneumonia throughout left
lower lobe, with left hilar, central mediastinal lymphadenopathy,
and “tree-in-bud” reticulonodularity identified throughout
the remainder of the lungs with scattered areas of noncavitary satellite nodularity, these findings likely representing
manifestations of endobronchial spread of infection throughout
the lungs (Figure 4).

Figure 2. Chest computed tomographic (CT) scan showing dense
consolidation involving the majority of the left lower lobe and trace left
pleural effusion.

After discharge from hospital, she reported worsening of her
symptoms and complained of fevers and chills, productive
cough with hemoptysis, dyspnea, pleuritic left sided chest
pain and worsening fatigue. She presented to our hospital for
evaluation of these symptoms about four days after discharge
from an outside hospital.

Figure 3. Chest X-ray (CXR) showing left lower lobe consolidation with
cavitary changes consistent with necrotizing pneumonia.
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Figure 4. Chest computed tomographic (CT) scan showing dense necrotizing bronchopneumonia seen throughout left lower lobe with left hilar,
central mediastinal lymphadenopathy, and “tree-in-bud” reticulonodularity identified throughout the remainder of lungs with scattered areas of
non-cavitary satellite nodularity.

The patient was admitted to the hospital with a diagnosis of nonresolving pneumonia. She was started on empiric intravenous
vancomycin and piperacillin/tazobactam. Sputum Gram’s
stain showed Gram-positive cocci in pairs and sputum culture
grew 2+ indigenous oral flora. Sputum for acid-fast bacilli was
negative, as was MRSA nasal PCR, viral respiratory panel, serum
interferon gamma release assay, human immunodeficiency
virus serology, urine streptococcal and legionella antigens, and
blood cultures. Procalcitonin level was 0.3 ng/mL.
Bronchoscopy was performed, it did not show any endobronchial
lesions. A large amount of purulent secretions were seen at
the superior segment of left lower lobe which were suctioned
out without difficulty. Bronchoalveolar lavage (BAL) and
transbronchial lung biopsies were obtained from left lower lobe
segments.
Despite being on intravenous antibiotics for four days, she
developed worsening of her clinical status. Repeat chest
X-ray (CXR) and chest computed tomographic (CT) scan were
obtained that showed worsening pneumonia with complete
consolidation of the left lower lobe and new patchy consolidation
and nodules in the right lung as shown in Figure 5 and Figure
6 respectively. Additional laboratory work up including fungal

Figure 5. Chest X-ray (CXR) showing persistent diffuse bilateral
pneumonia, left greater than right, with a moderate left-sided pleural
effusion.

Figure 6. Chest computed tomographic (CT) scan showing worsening diffuse pneumonia with complete consolidation of the left lower lobe, new
patchy consolidation in the left upper lobe/lingula and right lower lobe and new/enlarging nodules in the right lung. New small left pleural effusion
with fluid in the fissure and layering over the apex.
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blood cultures, urine Histoplasma antigen, serum Aspergillus
Galactomannan antigen by EIA, serum (1-3)-Beta-D-Glucan,
serum Coccidioides immitis antibodies were ordered. Fungal
blood cultures, Aspergillus Galactomannan antigen, serum
Coccidioides immitis antibodies were negative. Urine
Histoplasma antigen was detected and (1-3)-Beta-D-Glucan
was strongly positive at >500 pg/mL. (Less than 60 pg/mL
are interpreted as negative. 60 to 79 pg/mL are interpreted as
indeterminate).
Patient was empirically started on IV amphotericin B. The
transbronchial lung biopsy results from the left lower lobe
returned and showed numerous lymphocytes, histiocytes, many
multinucleated giant cells, forming ill-defined granulomas. The
biopsy also revealed the presence of thick-walled single yeast
forms of approximately 8–15 µm in size as shown in Figure 7a.
The organisms stained positively with Gomori methenamine
silver (GMS) stain as shown in Figure 7b. Some of these
yeast forms showed eccentric broad-based budding, overall
morphology was consistent with blastomycosis. Bronchial
biopsy and BAL cultures using Sabouraud Dextrose Agar (SDA)
showed growth of fungus as shown in Figures 8a, 8b and 8c.

Figure 7b. Gomori methenamine silver (GMS) (1000X magnification)
stain shows a budding yeast of Blastomyces dermatitidis with the
characteristic broad-based bud.

The patient showed significant clinical improvement on
antifungal treatment. She was treated with amphotericin for 2
weeks followed by oral itraconazole. She tolerated the treatment
well without any side effects. Follow-up imaging of the lungs
showed resolution of the pulmonary lesions.

Figure 8a. Phase-contrast microscopy: (1000X magnification): Shows
the typical appearance of Blastomyces dermatitidis. Round to oval shape,
thick, doubly refractile cell wall, and single broad-based bud.

Discussion

Figure 7a. Hematoxylin-and-eosin-stained section of left lower lobe
lung biopsy, low-power (Bottom) and high-power (Top) magnification,
shows numerous lymphocytes, histiocytes, many multinucleated giant
cells, forming ill-defined granulomas and presence of thick-walled single
yeast forms of approximately 8–15 µm in size with eccentric broad-based
budding overall morphology consistent with blastomycosis.

In this case report, we have described a case of progressive
acute pulmonary blastomycosis in a healthy adult living in
Kentucky, initially presenting with flu like illness with a left
sided consolidation on chest x-ray. This review focuses on the
epidemiological, clinical, diagnostic, and therapeutic aspects of
blastomycosis.
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Mycology
Blastomyces dermatitidis is a thermally dimorphic fungus. It
grows as the mycelial phase at room temperature and as the
yeast phase at 37ºC. This dimorphism appears to result from
a hybrid histidine kinase that senses host signals and triggers
the transition of Blastomyces dermatitidis from mold to yeast
form [6].

Pathogenesis

Figure 8b. Lacto-Phenol-Cotton-Blue Stain (LPCB) (1000X magnification):
Shows the mold form of Blastomyces dermatitidis characterized by
delicate, septate hyphae, unbranched conidiophores of rather short, yet
varying length extending from the hyphae. Conidia are produced singly at
the apex of the conidiophore or develop directly on the hyphae. Conidia are
unicellular, round to pyriform (tear drop) in shape (~2 to 10 µm dia.). Conidia
at the terminal end of the conidiophore resemble a “lollipop” in structure.

Blastomycosis pulmonary infection occurs by inhalation of the
conidia of Blastomyces dermatitidis. The conidia convert to
yeast phase in the lung. The yeast forms are more resistant to
phagocytosis and killing [7].
This is an important step in terms of pathogenesis because
this conversion results in a survival advantage and probably
contributes to infection by Blastomyces dermatitidis.
Blastomycosis is a systemic pyogranulomatous infection.
The typical inflammatory response consists of clusters of
neutrophils and noncaseating granulomas with epithelioid
and giant cells. This response is similar to that seen with other
dimorphic fungi including coccidioidomycosis, histoplasmosis,
and sporotrichosis.

Clinical Manifestations
The clinical spectrum of blastomycosis is varied, including
asymptomatic infection, acute or chronic pneumonia,
extrapulmonary and disseminated disease [8]. The lungs are
the most common site of infection, followed by the skin, bones,
and genitourinary system in decreasing order of frequency [9].
A subset of individuals with acute pulmonary blastomycosis
can progress to fulminant multi-lobar pneumonia and acute
respiratory distress syndrome [10]. Diagnostic delays are
not uncommon and often result in increased morbidity and
mortality.

Figure 8c. Bronchial and BAL culture using Sabouraud Dextrose Agar
(SDA): Blastomyces dermatitidis takes 2 to 3 weeks to grow at 25 to 30
degrees C. Blastomyces dermatitidis appears as white to beige cottony,
mold (mycelium) on Sabouraud dextrose agar.

Epidemiology
Most cases of blastomycosis have been reported in North
America. Endemic areas include the southeastern and southcentral states bordering the Mississippi and Ohio River basins,
the midwestern states and Canadian provinces bordering the
Great Lakes and Saint Lawrence Riverway [1-5]. Outside of
North America, blastomycosis has been reported in Africa with
occasional cases reported from Mexico, Central and South
America, India, and the Middle East.

Acute infection is frequently unrecognized unless related to a
cluster of cases or group exposure. The signs and symptoms of
acute pulmonary blastomycosis usually begin abruptly and may
be indistinguishable from viral or bacterial pneumonia [8]. Acute
blastomycosis may mimic other diseases [11]. This is due to the
variability of the presentation of blastomycosis and its relative
rarity. Our case is an example of how clinical presentation of
acute pulmonary blastomycosis may be initially considered as
community-acquired bacterial or viral pneumonia.
Acute pulmonary blastomycosis can also present with varied
radiographic findings. Alveolar infiltrates with or without
cavitation, mass lesions, and fibronodular infiltrates are most
common [8, 9]. The radiographic findings in our patient
included lobar and segmental alveolar infiltrates progressing
to cavitation, fibronodular infiltrates, tree in bud opacities,
hilar and mediastinal adenopathy, pleural effusion and diffuse
bilateral pulmonary involvement from presumed endobronchial
spread.
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Spontaneous resolution of acute pulmonary blastomycosis
has been reported, but its frequency is unknown [1, 12-14].
Although it has been reported that pulmonary blastomycosis in
some patients may resolve without therapy, our case reminds
us that previously healthy patients can have progression of
acute pulmonary blastomycosis. Hence, our case highlights the
importance of prompt diagnosis and institution of treatment in
all patients suspected to have acute pulmonary blastomycosis.
Also, cases have been reported where treatment of acute
pulmonary blastomycosis was withheld and patients later
presented with extra-pulmonary disease [15].
Though our patient did not develop severe respiratory failure
despite bilateral pulmonary involvement and endobronchial
spread of the lungs, blastomycosis is known to cause acute
respiratory distress syndrome with a high morbidity and
mortality [10] and therefore an early diagnosis coupled with
prompt treatment may lead to favorable outcomes.

Diagnosis
Due to the variability of the presentation of blastomycosis and
its relative rarity, a high index of suspicion and appropriate
microbiologic and histologic evaluation should be performed
when the diagnosis is uncertain and patients live in or have
traveled to areas endemic for blastomycosis.
No clinical syndrome or radiological features are absolutely
diagnostic of blastomycosis. The spectrum of disease that
Blastomyces dermatitidis causes overlaps with those of other
fungal pathogens and malignancy. Hence definitive diagnosis
requires the growth of the organism from clinical specimens
[8]. Unlike some fungi such as candida species, colonization
or contamination with Blastomyces dermatitidis does not
occur, which means that visualizing the organism on histology
or obtaining a positive culture confirms the diagnosis of
blastomycosis.
A presumptive diagnosis may be made by visualization of
the characteristic yeast form in clinical specimens including
histopathology or by culture of the organism in body fluids or
tissue. In the appropriate clinical setting, visualization of the
fungus can prompt the initiation of antimicrobial therapy.
Diagnosis can be established by examination of wet preparations
of clinical specimens (10% KOH and/or calcofluor white) but
they have a low diagnostic yield (36-46%) [16]. Despite these
low diagnostic results, the simplicity and the low cost of the
procedure, as well as the potential for rapid diagnosis, justify a
wet preparation on all clinical specimens.
Cytology has been shown to be particularly useful in diagnosis,
permitting identification of the etiologic agent in 56% of
all cases and 72% of pulmonary cases of blastomycosis in
a retrospective study [17]. When visualized, the yeast cells
are easily differentiated from others on the basis of their size
(8–15 µm in diameter), multinucleate with thick refractile cell
wall, and single, broad-based buds. Bronchoscopy is useful
for diagnosis, especially in patients who are not producing
sputum or in whom the radiograph indicates the possibility of
malignancy [16]. Bronchial washings, lavage fluid, and postbronchoscopy sputum samples should be sent for cytology

as well as smear and culture because the organism is often
visualized on Papanicolaou preparations [18]. Papanicolaou
staining of respiratory tract specimens has a high diagnostic
yield (93%); the organism appears to be refractile and pale bluegreen with this stain.
A pyogranulomatous tissue response is frequently seen in
blastomycosis and should signal the possibility of this fungus.
The characteristic host response to infection with Blastomyces
dermatitidis is a mixed inﬂammatory reaction with clusters
of polymorphonuclear leukocytes and granulomas, usually
noncaseating, with epitheloid histiocytes and giant cells,
primarily the foreign body type.
Identification of Blastomyces dermatitidis in hematoxylin-eosin
(H & E) stained histopathologic specimens is often difficult, and
special stains, such as Gomori methenamine-silver (GMS) or
periodic acid-Schiff (PAS) are useful in examining the tissue for
the presence of fungal elements. Serology is not useful for the
diagnosis of blastomycosis due to high degree of cross-reactivity
shared by other endemic mycoses especially Histoplasma
capsulatum [19, 20]. The urine of patients with blastomycosis
may contain cross-reactive or shared antigens with H.
capsulatum var. capsulatum; in one study, 12 of 19 patients
with blastomycosis tested positive with the H. capsulatum urine
antigen assay [20]. This was noted in our case as well.
Although not an antigen test, detection of (1-3)-Beta-D-Glucan
in serum has been shown to be a useful adjunct for diagnosis of
invasive fungal infections, especially candidiasis, aspergillosis,
and histoplasmosis [21-23]. In contrast, preliminary data
suggest that the test is not of value with patients with
blastomycosis. In a very small study of four patients with
microbiologically proven Blastomyces dermatitidis infection,
(1-3)-Beta-D-Glucan was detected in only one patient, who had
chronic disseminated disease with multiple skin lesions [24].
Our patient had a strongly positive (1-3)-Beta-D-Glucan.
Culture of Blastomyces dermatitidis from environmental
sources remains difficult, in patients with pulmonary
blastomycosis, sputum culture has a high positive yield (e.g.,
75% per single sample, 86% per patient) [16]. Specimens
obtained for culture by bronchoscopy yielded a positive
diagnosis in 92% of patients. Any material obtained should be
placed on Sabouraud agar or, preferably, more enriched agar
(e.g., Sabhi, brain-heart infusion, Gorman medium). Because
initial growth is more dependable at 30°C, this temperature
is recommended. Specimens contaminated with bacteria
should also be cultured on medium containing an antibacterial
antibiotic such as chloramphenicol. The mycelial form of
Blastomyces dermatitidis is not diagnostic, and conversion to
the yeast form is required for confirmation. Early identification
of mycelial cultures is possible with commercially available
chemiluminescent DNA probes that recognize unique RNA
sequences of Blastomyces dermatitidis [25].

Differential Diagnosis
Endospores of Coccidioides immitis may resemble single yeast
cells, but the presence of budding can be used to distinguish
Blastomyces dermatitidis. While yeast forms of Blastomyces
dermatitidis as described in our case report, show broad based
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budding, Paracoccidioides brasiliensis, rarely seen in the
United States, is distinguished by the presence of multiple,
narrow-based buds. Blastomyces dermatitidis may sometimes
be as small as Cryptococcus neoformans, although the capsule
and narrow-based bud of the latter, aid in differentiation.

Treatment
The greatest challenge in making the diagnosis of blastomycosis
is considering it in the ﬁrst place. Although the disease can be
fatal, most patients are cured with antifungal therapy.
Before the availability of chemotherapy for treatment of
blastomycosis, the disease as reported had a progressive course
with eventual extrapulmonary disease and a mortality rate
exceeding 60%. Even though isolated cutaneous disease had a
better prognosis, skin lesions were progressive, and spontaneous
recovery was uncommon. Thus, after the introduction of
effective antifungal therapy, it was accepted that all patients
with blastomycosis should be treated.
Amphotericin B (AmB) was previously considered the
treatment of choice for all clinical forms of blastomycosis [26,
27]. However, ketoconazole, itraconazole, and fluconazole are
effective alternatives for immunocompetent patients with mild
to moderate disease.
The Infectious Diseases Society of America (IDSA) has
published clinical practice guidelines that are based upon openlabel studies, case reports, and expert opinion.
AmB remains the drug of choice for blastomycosis with life
threatening disease or with central nervous system involvement,
for patients who are immunocompromised or for whom azole
treatment has failed [27].
For moderate to severe pulmonary disease, current guidelines
recommend treatment with a lipid formulation of AmB at a
dosage of 3–5mg/kg per day intravenous or AmB deoxycholate
at a dosage of 0.7–1mg/kg per day intravenous for 1-2 weeks or
until improvement is noted, followed by oral itraconazole [27].
However, the cost and toxicity are substantial, especially of AmB
deoxycholate. Among the azole antifungals, ketoconazole was
the first one used with success in treatment of blastomycosis.
However, in the current IDSA guidelines for Blastomycosis,
itraconazole has replaced ketoconazole as the azole of choice for
its better antimycotic effect, better tolerability, and higher (up to
95%) rate of cure [27]. Treatment duration is 6–12 months or
till resolution of radiological abnormalities.
Current guidelines recommend step-down therapy to an
azole after an initial therapeutic response to AmB. Patients
who are immunocompetent and do not have central nervous
system disease may be switched to step-down therapy of oral
itraconazole, 200 mg orally three times daily for three days,
followed by 200 mg twice daily for 6 to 12 months [27]. Relapse
rates of most patients treated with AmB are <5%. Relapse is
more common in immunocompromised patients, especially
those with acquired immune deficiency syndrome [27]. Some
authorities recommend lifelong suppressive therapy with
itraconazole [27]. These patients still require close follow-up.

Prevention
Vaccine to prevent blastomycosis is not available. There is
no data to suggest that modifying individual behavior would
change the incidence of the blastomycosis [11]. Blastomyces
dermatitidis is not transmitted from person to person, and
therefore, blastomycosis is generally not contagious. Pets,
particularly dogs, can get blastomycosis, but it is not contagious
between animals and people [28]. Blastomycosis is uncommon,
even in areas in which the disease is endemic.
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